Immunocore Holdings Ltd (IMCR) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Immunocore Holdings Ltd stock (IMCR) is currently trading at $30.28. Immunocore Holdings Ltd PS ratio (Price-to-Sales) is 3.79. Analyst consensus price target for IMCR is $63.86. WallStSmart rates IMCR as Sell.
- IMCR PE ratio analysis and historical PE chart
- IMCR PS ratio (Price-to-Sales) history and trend
- IMCR intrinsic value — DCF, Graham Number, EPV models
- IMCR stock price prediction 2025 2026 2027 2028 2029 2030
- IMCR fair value vs current price
- IMCR insider transactions and insider buying
- Is IMCR undervalued or overvalued?
- Immunocore Holdings Ltd financial analysis — revenue, earnings, cash flow
- IMCR Piotroski F-Score and Altman Z-Score
- IMCR analyst price target and Smart Rating
Immunocore Holdings
📊 No data available
Try selecting a different time range
Smart Analysis
Immunocore Holdings Ltd (IMCR) · 9 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in revenue growth, eps growth, institutional own.. Concerns around return on equity and operating margin. Mixed signals suggest waiting for clearer direction before acting.
Immunocore Holdings Ltd (IMCR) Key Strengths (3)
Earnings per share surging 822.00% year-over-year
99.19% of shares held by major funds and institutions
Strong revenue growth at 24.30% annually
Supporting Valuation Data
Immunocore Holdings Ltd (IMCR) Areas to Watch (6)
Company is destroying shareholder value
Company is losing money with a negative profit margin
Near-zero operating margins, business under pressure
Premium pricing at 4.0x book value
Small-cap company with higher risk but more growth potential
Revenue is fairly priced at 3.79x sales
Immunocore Holdings Ltd (IMCR) Detailed Analysis Report
Overall Assessment
This company scores 43/100 in our Smart Analysis, earning a D grade. Out of 9 metrics analyzed, 3 register as strengths (avg 9.3/10) while 6 fall into concern territory (avg 2.7/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on EPS Growth, Institutional Own., Revenue Growth. Growth metrics are encouraging with Revenue Growth at 24.30%, EPS Growth at 822.00%.
The Bear Case
The primary concerns are Return on Equity, Profit Margin, Operating Margin. Some valuation metrics including Price/Sales (3.79), Price/Book (3.98) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -9.58%, Operating Margin at 0.04%, Profit Margin at -8.88%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -9.58% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 24.30% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Profit Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
IMCR Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
IMCR's Price-to-Sales ratio of 3.79x sits near its historical average of 3.96x (14th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 9% below its historical high of 4.17x set in Mar 2026, and 0% above its historical low of 3.79x in Mar 2026.
WallStSmart Analysis Synopsis
Data-driven financial summary for Immunocore Holdings Ltd (IMCR) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Immunocore Holdings Ltd is a strong growth company balancing expansion with improving profitability. Revenue reached 400M with 24% growth year-over-year. The company is currently unprofitable, posting a -8.9% profit margin.
Key Findings
The company is unprofitable with a -8.9% profit margin. The path to breakeven will be the key catalyst.
Free cash flow is -36M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Growth sustainability: can Immunocore Holdings Ltd maintain 24%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Immunocore Holdings Ltd.
Bottom Line
Immunocore Holdings Ltd offers an attractive blend of growth (24% revenue expansion) and improving fundamentals. The company is transitioning from pure growth to profitable growth, a critical inflection point. Watch for sustained margin expansion as the key signal.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Immunocore Holdings Ltd(IMCR)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Immunocore Holdings Limited, an advanced stage biotechnology company, develops immunotherapies for the treatment of cancer, infectious and autoimmune diseases. The company is headquartered in Abingdon, the United Kingdom.